ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric CancerGlobeNewsWire • 10/03/23
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric CancerGlobeNewsWire • 10/02/23
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program UpdateGlobeNewsWire • 08/10/23
ALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 08/10/23
ALX Oncology Holdings Inc. (ALXO) Loses -18.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 07/26/23
ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric CancerGlobeNewsWire • 06/26/23
ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational HighlightsGlobeNewsWire • 05/11/23
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian CancerGlobeNewsWire • 05/09/23
ALX Oncology and Quantum Leap Healthcare CollaborativeTM Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast CancerPRNewsWire • 03/14/23
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast CancerGlobeNewsWire • 03/13/23
ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming MilestonesGlobeNewsWire • 03/09/23
ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial CancerGlobeNewsWire • 02/16/23
ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid LeukemiaGlobeNewsWire • 12/12/22
ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational HighlightsGlobeNewsWire • 11/08/22
ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual MeetingGlobeNewsWire • 11/03/22
ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of EvorpaceptGlobeNewsWire • 10/31/22
ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingGlobeNewsWire • 10/05/22
ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc ConferenceGlobeNewsWire • 09/21/22
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast CancerPRNewsWire • 08/16/22